

Frits I Mulder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5699069/publications.pdf>

Version: 2024-02-01

16
papers

975
citations

840776

11
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

895
citing authors

#	ARTICLE	IF	CITATIONS
1	Venous thromboembolism in cancer patients: a population-based cohort study. <i>Blood</i> , 2021, 137, 1959-1969.	1.4	277
2	The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. <i>Haematologica</i> , 2019, 104, 1277-1287.	3.5	197
3	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1439-1449.	3.4	154
4	Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. <i>Blood</i> , 2020, 136, 1433-1441.	1.4	106
5	Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study. <i>Thrombosis Research</i> , 2020, 185, 13-19.	1.7	52
6	Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis. <i>Blood Advances</i> , 2020, 4, 5215-5225.	5.2	35
7	Arterial Thromboembolism in Cancer Patients. <i>JACC: CardioOncology</i> , 2021, 3, 205-218.	4.0	33
8	Clinical implications of incidental venous thromboembolism in cancer patients. <i>European Respiratory Journal</i> , 2020, 55, 1901697.	6.7	31
9	Pulmonary embolism at autopsy in cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1228-1235.	3.8	24
10	Primary Thromboprophylaxis in Ambulatory Cancer Patients: Where Do We Stand?. <i>Cancers</i> , 2020, 12, 367.	3.7	15
11	Evaluation of the Khorana, PROTECHT, and 5â€NP scores for prediction of venous thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2974-2983.	3.8	14
12	Risk scores for occult cancer in patients with unprovoked venous thromboembolism: Results from an individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2622-2628.	3.8	10
13	Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3008-3017.	3.8	10
14	Growth differentiation factorâ€15 for prediction of bleeding in cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 20, 138.	3.8	8
15	The Ottawa score performs poorly in cancer patients with incidental pulmonary embolism. <i>Thrombosis Research</i> , 2019, 181, 59-63.	1.7	5
16	Thromboembolic and bleeding complications in patients with oesophageal cancer. <i>British Journal of Surgery</i> , 2020, 107, 1324-1333.	0.3	4